- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04268615
Covert Saccade Triggers in Bilateral Vestibular Hypofunction (CS-TRIGGER)
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69500
- Hospices Civils de Lyon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For all :
- Age from 18 to 90
- Understanding of the experimental instructions
- Informed Consent
- For Patients :
Bilateral vestibular hypofunction with regards to the criteria of the of the Barany Society A. Chronic vestibular syndrome with at least three of the following symptoms
- Postural imbalance
- Unsteadiness of gait
- Movement-induced blurred vision or oscillopsia during walking or quick head/body movements
Worsening of postural imbalance or unsteadiness of gait in darkness and/or on uneven ground B. No symptoms while sitting or lying down under static conditions C. Bilaterally reduced or absent angular VOR function documented by
- bilaterally pathological horizontal angular VOR gain < 0.6, measured by the video-HIT5or scleral-coil technique and/or
- reduced caloric response (sum of bithermal max. peak SPV on each side < 6°/sec7)and/or
- reduced horizontal angular VOR gain < 0.1 upon sinusoidal stimulation on a rotatorychair (0.1 Hz, Vmax = 50°/sec).
D. Not better accounted for by another disease
* For Healthy control No ENT or neurological disorders
Exclusion Criteria:
- Corrected Visual Acuity lower than 5/10
- Other conditions leading to oscillopsia or ataxia
- Oculomotor palsy, ocular instability in primary position
- Treatment that may affect ocular motility (psychotropes)
- Cervical rachis pathology with instability
- Cochlear Implants
- Non-stabilized medical disease
- Pregnant women
- Patients under tutelage
- Patient without social security
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients
Patients suffering from chronic bilateral vestibular hypofunction
|
During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets.
During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene.
Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
|
Active Comparator: healthy subject group
|
During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets.
During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene.
Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Latency of covert-saccades
Time Frame: Day 1
|
Latency of covert saccades correspond to the time between the beginning of head impulse and the initiation of the first covert-saccade
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of covert-saccades
Time Frame: Day 1
|
Frequency of covert saccades corresponds to the total amount of covert-saccades divided by the total amount of head impulse tests multiplied by 100.
|
Day 1
|
Velocity of covert-saccades
Time Frame: day 1
|
Velocity of covert saccades correspond to the maximal velocity of the first covert-saccade
|
day 1
|
Amplitude of covert-saccades
Time Frame: Day 1
|
Amplitude of covert saccades correspond to amplitude of the first covert-saccade
|
Day 1
|
Latency of visually-guided saccades
Time Frame: Day 1
|
Latency of visually guided saccades correspond to the time between the appearance of target and the initiation of the first saccade
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Caroline FROMENT, MD, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL19_0998
- 2020-A00184-35 (Other Identifier: ID-RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Covert Saccades and Virtual Reality
-
Institut National de la Santé Et de la Recherche...Not yet recruitingSchizophrenia | Bipolar Disorder
-
Eskisehir Osmangazi UniversityNot yet recruiting
-
Hacettepe UniversityRecruitingGonarthrosis; PrimaryTurkey
-
Istituto Auxologico ItalianoCompletedGeneralized Anxiety DisorderItaly
-
The University of Hong KongRecruiting
-
Universidad Rey Juan CarlosCompleted
-
University of PennsylvaniaNot yet recruitingEnd Stage Kidney Disease
-
Dokuz Eylul UniversityCompletedPain, Acute | Anxiety State | Fear | Emotional DistressTurkey
-
National University of MalaysiaRecruitingPleural EffusionMalaysia
-
Stanford UniversityTerminatedConversion Disorder | Non-epileptic Seizures | Functional Neurological Disorder | Functional Movement Disorder | Psychogenic Movement DisorderUnited States